


**Product Name: 2-Chloro-5,6,7,8-tetrahydro-1,6-naphthyridine
hydrochloride**

Catalog Number: L14619



Sizes Available: 1 g, 5 g, 25 g, and larger sizes available

Molecular weight: 205.08 g/mol

Molecular Formula: C₈H₁₀Cl₂N₂

CAS Number: 766545-20-4

Storage: Store at 2-8 C°, under dry conditions.

Synonyms: None found

Uses: Synthesis building block, Organic Synthesis, 1,6-naphthyridine nitrogen heterocycle, synthesis, chlorine reactions, amine reactions

2-Chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride, is a synthetic fine chemical useful in the synthesis of pharmaceuticals and fine organic chemicals.

Selected Patents and References:

Aebi, J.; Amrein, K.; Chen, W.; Hornsperger, B.; Kuhn, B.; Liu, Y.; Maerki, H. P.; Mayweg, A. V.; Mohr, P.; Tan, X.; Wang, Z.; Zhou, M. [New bicyclic dihydroisoquinolin-1-one derivatives as aldosterone synthase inhibitors and their preparation](#). WO2013079452A1, 2013.

Ashton, W. T.; Caldwell, C. G.; Duffy, J. L.; Mathvink, R. J.; Wang, L.; Weber, A. E. [3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes](#). WO2004069162A2, 2004.

Benbow, J. W. [Preparation of substituted 2H-\[1,2,4\]triazolo\[4,3-a\]pyrazines as GSK-3 inhibitors](#). WO2005035532A1, 2005.

Benbow, J. W.; Chu-Moyer, M. Y.; Kung, D. W. [Preparation of substituted 4-amino\[1,2,4\]triazolo\[4,3-a\]quinoxalines for treating glycogen synthase kinase 3 \(GSK-3\) mediated conditions](#). US20040192698A1, 2004.

Blagg, J.; Fray, M. J.; Lewis, M. L.; Mathias, J. P.; Stefaniak, M. H.; Stobie, A. [Preparation of alkoxy quinazolinone compounds as \$\alpha\$ 1L adrenoceptors antagonists useful in therapy](#). WO2003076427A1, 2003.

Buchanan, J. L.; Bregman, H.; Chakka, N.; Dimauro, E. F.; Du, B.; Nguyen, H. N.; Zheng, X. M. Preparation of triazine compounds as inhibitors of voltage-gated sodium channels for treating chronic pain disorders. WO2010022055A2, 2010.

Chen, L.; Yang, Y.; Liu, L.; Gao, Q.; Xu, S., [Iridium-Catalyzed Enantioselective \$\alpha\$ -C\(sp³\)-H Borylation of Azacycles](#). *J. Am. Chem. Soc.* **2020**, *142* (28), 12062-12068.

Fox, D. N. A. [Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia](#). WO9830560A1, 1998

Li, Z.; Wang, X.; Eksterowicz, J.; Gribble, M. W.; Alba, G. Q.; Ayres, M.; Carlson, T. J.; Chen, A.; Chen, X.; Cho, R.; Connors, R. V.; DeGraffenreid, M.; Deignan, J. T.; Duquette, J.; Fan, P.; Fisher, B.; Fu, J.; Huard, J. N.; Kaizerman, J.; Keegan, K. S.; Li, C.; Li, K.; Li, Y.; Liang, L.; Liu, W.; Lively, S. E.; Lo, M.-C.; Ma, J.; McMinn, D. L.; Mihalic, J. T.; Modi, K.; Ngo, R.; Pattabiraman, K.; Piper, D. E.; Queva, C.; Ragains, M. L.; Suchomel, J.; Thibault, S.; Walker, N.; Wang, X.; Wang, Z.; Wanska, M.; Wehn, P. M.; Weidner, M. F.; Zhang, A. J.; Zhao, X.; Kamb, A.; Wickramasinghe, D.; Dai, K.; McGee, L. R.; Medina, J. C., [Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3](#). *J. Med. Chem.* **2014**, *57* (8), 3430-3449.

10.Orwat, M. J.; Pinto, D. J. P.; Smith, L. M., II; Srivastava, S.; Corte, J. R. [Preparation of substituted tetrahydroisoquinoline compounds as factor Xla inhibitors](#). WO2013055984A1, 2013.

Hazardous Properties and Cautions: The toxicological and pharmacological properties of this compound are not fully known. For further information see the MSDS on request. **2-Chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride** is manufactured, shipped according to standard practices, and intended for research and development in a laboratory utilizing prudent procedures for handling chemicals of unknown toxicity, under the supervision of persons technically qualified to evaluate potential risks and authorized to enforce appropriate health and safety measures. As with all research chemicals, precautions should be taken to avoid unnecessary exposures or risks.

Warranty and Disclaimer: Frontier Scientific, Inc. warrants the product conforms to the specifications stated herein. In the event of nonconformity, Frontier will replace products or refund purchase price, at its sole option, and Frontier shall not be responsible for any other loss or damage, whether known or foreseeable to Frontier. No other warranties apply, express or implied, including but not limited to warranty of fitness for any purpose or implied warranty of merchantability. Purchaser is solely responsible for all consequences of its use of the product and Frontier assumes no responsibility therefore,) including success of purchaser's research and development, or health or safety of any uses of the product.

